BioCentury
ARTICLE | Clinical News

CL-108 regulatory update

February 8, 2017 10:48 PM UTC

FDA issued a complete response letter for an NDA from Charleston and Daiichi for CL-108 to manage pain severe enough to require an opioid analgesic while preventing or reducing the associated opioid-i...